Healthcare

19.3% Weight Loss at Week 48: Phase Ⅲ Data of Olatorepatide, Hansoh's Dual‑Biased GLP‑1/GIP Agonist, Presented at EASD

MILAN, Oct. 2, 2026, 00:00 GMT-04

Hansoh-Pharma

Read full article →

Uriage Presents New Scientific Advances in Triple Barrier Science at EADV Congress 2026 in Vienna

PARIS, Oct. 1, 2026, 15:18 GMT-04

Laboratoires-Dermatol

Read full article →

82-Year-Old Dr. Judy Benjamin traversed southern England to share her story and advocate for families affected by Alzheimer's

LONDON, Oct. 1, 2026, 13:41 GMT-04

Apollo-Health

Read full article →

Fabry Disease Market Outlook: 6 Upcoming Therapies Set to Influence the Future Market Landscape | DelveInsight

LAS VEGAS, Oct. 1, 2026, 10:31 GMT-04

DelveInsight-Business

Read full article →

Healthcare Supply Chain Management Market worth $5.31 billion by 2031 - Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., Oct. 1, 2026, 10:30 GMT-04

MarketsandMarkets

Read full article →

A Formidable Type of Childhood Cancer Gets Added to Highly Regarded Library of Treatment Recommendations

PLYMOUTH MEETING, Pa., Oct. 1, 2026, 09:36 GMT-04

NCCN

Read full article →

Waters Corporation Schedules Third Quarter 2026 Earnings Conference Call

MILFORD, Mass., Oct. 1, 2026, 09:00 GMT-04

Waters-Corporation

Read full article →

Medline launches "10 Minutes That Matter" campaign to spotlight the value of time in the operating theatre

UTRECHT, Netherlands, Oct. 1, 2026, 07:31 GMT-04

Medline-EMEA

Read full article →

HelpMeSee Names Doug May President and Chief Executive Officer

JERSEY CITY, N.J., Oct. 1, 2026, 07:07 GMT-04

Help-Me-See

Read full article →

Lutris Pharma Announces Positive Updated Phase 2 Data Demonstrating Durable, Mechanism-Directed Benefit of LUT014 Gel for EGFRI-Induced Acneiform Rash at the EADV Congress

TEL AVIV, Israel, Oct. 1, 2026, 07:03 GMT-04

Lutris-Pharma

Read full article →

Brainomix Announces New Phase III INBUILD® Data Highlighting Potential of Quantitative CT to Predict Disease Progression and Assess Treatment Response in Progressive Pulmonary Fibrosis

OXFORD, England and CHICAGO, Oct. 1, 2026, 07:00 GMT-04

Brainomix

Read full article →

Biopesticides Market worth $20.32 billion by 2031- Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., Oct. 1, 2026, 06:40 GMT-04

MarketsandMarkets

Read full article →

Compression Therapy Market to Reach USD 5.76 Bn by 2031 Driven by Rising Venous Disorders and Advanced Compression Technologies, Says Mordor Intelligence

HYDERABAD, India, Oct. 1, 2026, 06:30 GMT-04

Mordor-Intelligence-P

Read full article →

Ensera launches alliance network with SHL Medical, Stevanato Group, Ypsomed, Argonaut and American Injectables

DUBLIN, Oct. 1, 2026, 04:00 GMT-04

Ensera

Read full article →

SciBase announces outcome of rights issue of shares

STOCKHOLM, Oct. 1, 2026, 03:17 GMT-04

SciBase

Read full article →

Lundbeck announces headline results from Phase IV THRIVE trial evaluating VYEPTI® (eptinezumab) following inadequate response to prior CGRP-targeting preventive therapy

VALBY, Denmark, Oct. 1, 2026, 02:22 GMT-04

H-Lundbeck-AS

Read full article →

Fresenius completes acquisition of mAbxience, creating a stronger platform for future portfolio expansion

MADRID, Oct. 1, 2026, 01:00 GMT-04

mAbxience-Expansion

Read full article →

Emerald Clinical Trials Appoints Michael Stibilj as Chief Executive Officer to Lead Next Phase of Global Growth

SINGAPORE, Oct. 1, 2026, 23:00 GMT-04

Emerald-Clinical-Tria

Read full article →

Oncology Conference Coverage Services: How DelveInsight Helps Pharma Teams Find Opportunities in a Fast-Moving Oncology Landscape

LAS VEGAS, Sept. 30, 2026, 10:46 GMT-04

DelveInsight-Business

Read full article →

Vasomotor Symptoms Market Poised for Growth Through 2036, Driven by Rising Adoption of Hormonal and Non-Hormonal Therapies | DelveInsight

LAS VEGAS, Sept. 30, 2026, 10:31 GMT-04

DelveInsight-Business

Read full article →